Janux Therapeutics (JANX) Receivables (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Receivables data on file, last reported at $42.5 million in Q1 2026.

• On a quarterly basis, Receivables changed N/A year-over-year to $42.5 million in Q1 2026; TTM through Mar 2026 was $42.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $6.4 million, changed N/A from the prior year.
• Receivables for Q1 2026 stood at $42.5 million, up from $6.4 million in the prior quarter.
• Over the last five years, Receivables for JANX reached as high as $42.5 million in Q1 2026 and fell as low as $500000.0 in Q3 2022.
• Historically, Receivables has averaged $9.8 million across 5 years, with a median of $4.4 million in 2024.
• On a YoY basis, Receivables climbed as much as 484.8% in 2024 and fell as far as 484.8% in 2024.
• Year by year, Receivables stood at $500000.0 in 2022, then soared by 332.2% to $2.2 million in 2023, then soared by 457.89% to $12.1 million in 2024, then plunged by 46.68% to $6.4 million in 2025, then jumped by 560.59% to $42.5 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $42.5 million in Q1 2026, $6.4 million in Q4 2025, and $12.1 million in Q2 2024.